Zenas BioPharma, Inc. (ZBIO)
| Market Cap | 1.28B +321.0% |
| Revenue (ttm) | 10.00M +100.0% |
| Net Income | -377.74M |
| EPS | -8.44 |
| Shares Out | 57.36M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,323,069 |
| Open | 23.48 |
| Previous Close | 23.37 |
| Day's Range | 21.00 - 24.08 |
| 52-Week Range | 6.11 - 44.60 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 42.14 (+88.97%) |
| Earnings Date | Mar 16, 2026 |
About ZBIO
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and FcγRIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a CTLA-4-Ig fusion protein designed to have an ext... [Read more]
Financial Performance
In 2025, Zenas BioPharma's revenue was $10.00 million, an increase of 100.00% compared to the previous year's $5.00 million. Losses were -$377.74 million, 140.6% more than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for ZBIO stock is "Strong Buy." The 12-month stock price target is $42.14, which is an increase of 88.97% from the latest price.
News
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the...
Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
- Obexelimab marketing applications for the treatment of IgG4-RD expected to be submitted to the FDA in Q2 2026 and the EMA in H2 2026 based on the Phase 3 INDIGO trial results - - Topline results of ...
Zenas BioPharma Announces Late-Breaking Platform Presentation of Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis at ACTRIMS Forum 2026
- Obexelimab met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo over weeks 8 and 12 (p=0.0009) -
Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the ...
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the ...
Zenas BioPharma, Inc. (ZBIO) Discusses Positive Phase 3 INDIGO Trial Results for Obexelimab in IgG4-Related Disease Transcript
Zenas BioPharma, Inc. (ZBIO) Discusses Positive Phase 3 INDIGO Trial Results for Obexelimab in IgG4-Related Disease Transcript
Why Zenas BioPharma's Selloff Was Structurally Inevitable
Zenas BioPharma (NASDAQ: ZBIO) shares fell more than 50% in the last trading session following the release of Phase 3 results for obexelimab in patients with immunoglobulin G4-related disease (IgG4-RD...
Zenas: Maintaining 'Strong Buy' As Cross-Trial Comparison Of Obexelimab Should Not Be A Factor
Zenas BioPharma remains a 'Strong Buy' after Obexelimab met the phase 3 INDIGO primary endpoint in IgG4-RD, despite a sharp stock decline. The company's pipeline is advancing with Orelabrutinib, a pot...
Zenas BioPharma Touts Phase 3 Win, But Stock Crashes
Zenas BioPharma Inc. (NASDAQ: ZBIO) stock is trading lower on Monday after the company released results from the Phase 3 INDIGO trial of obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD).
Zenas BioPharma's immune disorder drug meets main goal in late-stage trial
Zenas BioPharma said on Monday its experimental drug cut the risk of disease flare-ups in a late-stage study of patients with a rare immune system-related condition that can damage organs over time.
Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
- Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD flare -
Zenas BioPharma's Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus
- Orelabrutinib is the first BTK inhibitor to demonstrate significant clinical activity in a Phase 2 clinical trial for SLE - - Zenas acquired the exclusive right to develop, manufacture and commercia...
Zenas Prepares For INDIGO Phase 3 Readout - Reinstating Buy Rating
Zenas BioPharma is rated a buy ahead of the pivotal INDIGO Phase 3 trial readout for obexelimab in IgG4-RD, expected by year-end. ZBIO's strong balance sheet, with $301.6M in cash and runway into late...
Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update
- Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 -
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
WALTHAM, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the ...
Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis
- Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 -
Zenas BioPharma: Two Late-Stage Catalysts And A $2B InnoCare Deal
Zenas BioPharma (ZBIO) secures a $2B licensing deal with InnoCare, expanding its pipeline with orelabrutinib for global non-oncology indications. ZBIO's two late-stage candidates, obexelimab and orela...
Zenas Bio inks potential $2 billion licensing deal with China's InnoCare for autoimmune drug
Zenas BioPharma said on Wednesday it has secured global rights to develop and commercialize an experimental drug from China-based InnoCare Pharma for multiple sclerosis and other autoimmune conditions...
Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis
- Orelabrutinib, a highly selective CNS-penetrant, oral small molecule Bruton's Tyrosine Kinase (BTK) inhibitor with best-in-class potential now in Phase 3 development for progressive forms of Multipl...
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million
- Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease - - Additional $150 million associated with the upcoming results of the obexe...
Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
- Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 -
Zenas Biopharma: A Risky Buy On Upcoming Data Readouts In IgG4, MS
Zenas BioPharma, Inc.'s Obexelimab offers a differentiated, non-depleting B-cell inhibition approach, with promising Phase 2 data in IgG4 and upcoming pivotal catalysts in 2025. The lead asset's block...
FINAL ALERT NOTICE - ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO
LOS ANGELES , June 16, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Zenas Biopharma, Inc. ("Zenas" or "the Company") (NASDAQ: ZBIO) for violations of the ...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Zenas To Contact Him Directly To Discuss Their Options If you purch...